Meeting
2020 ASCO Virtual Scientific Program
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
Authors
Andreas Nicholas Saltos
Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL
Andreas Nicholas Saltos , Tawee Tanvetyanon , Ben C. Creelan , Michael Rahman Shafique , Scott Joseph Antonia , Eric B. Haura , Hong Zheng , Margaret Barlow , James Saller , Anna Castellano-Fornelli , Antoine Richards , Ram Thapa , Theresa A. Boyle , Dung-Tsa Chen , Amer A Beg , Jhanelle Elaine Gray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02638090
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9567)
DOI
10.1200/JCO.2020.38.15_suppl.9567
Abstract #
9567
Poster Bd #
333
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.
First Author: Andreas Nicholas Saltos
Poster
2018 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
First Author: Andreas Nicholas Saltos
Poster
2023 ASCO Annual Meeting
Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).
First Author: Christophe Le Tourneau
Poster
2022 ASCO Annual Meeting
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach.
First Author: Marina Chiara Garassino